Mark Lichty, 73, said it took a decade for him to overcome the anxiety, fear of death, and uncertainty about the future after he was diagnosed with low-grade prostate cancer in 2005.
The 2022 guidance for the first time makes active surveillance the recommended treatment for select patients with favorable intermediate-risk Gleason 3+4 prostate cancer.